Yarrow Bioscience (YARW) Share-based Compensation (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Share-based Compensation came in at $474000.0 in Q1 2026, down 37.88% YoY from $763000.0 in Q1 2025, and up 163.2% on a QoQ basis from -$750000.0 in Q2 2025.
Yarrow Bioscience (YARW) Share-based Compensation (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Share-based Compensation data on file, last reported at $474000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 37.88% year-over-year to $474000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 61.51% YoY) and the FY2025 annual result came in at $16000.0, down 99.52% from the prior year.
- Share-based Compensation rose to $474000.0 in Q1 2026, from -$750000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q3 2022 to a low of -$3.2 million in Q4 2022.
- A 5-year average of $266466.7 and a median of $734000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 2253.33% — and 2024, when it surged 292.7%.
- Tracing YARW's Share-based Compensation over 5 years: stood at -$3.2 million in 2022, then surged by 105.51% to $178000.0 in 2023, then surged by 292.7% to $699000.0 in 2024, then plunged by 207.3% to -$750000.0 in 2025, then jumped by 163.2% to $474000.0 in 2026.
- The last three Share-based Compensation figures came in at $474000.0 (Q1 2026), -$750000.0 (Q2 2025), and $763000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 436,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 436,000.00 |
| Jun 30, 2026 | 436,000.00 |
| Mar 31, 2026 | 474,000.00 |
| Mar 31, 2026 | 474,000.00 |
| Jun 30, 2025 | -750,000.00 |
| Jun 30, 2025 | -750,000.00 |
| Mar 31, 2025 | 763,000.00 |
| Mar 31, 2025 | 763,000.00 |
| Dec 31, 2024 | 699,000.00 |
| Dec 31, 2024 | 699,000.00 |
| Sep 30, 2024 | 734,000.00 |
| Sep 30, 2024 | 734,000.00 |
| Jun 30, 2024 | 885,000.00 |
| Jun 30, 2024 | 885,000.00 |
| Mar 31, 2024 | 985,000.00 |
| Mar 31, 2024 | 985,000.00 |
| Dec 31, 2023 | 178,000.00 |
| Dec 31, 2023 | 178,000.00 |
| Sep 30, 2023 | -1.70 Mn |
| Sep 30, 2023 | -1.70 Mn |